Scotland’s AI powerhouse driving healthtech growth

Tern plc

Scotland’s reputation as a data and AI powerhouse is no accident. With Edinburgh now crowned the UK’s top city for artificial intelligence, particularly in healthcare, the nation’s long-term investments in talent, infrastructure, and ethical leadership are paying off. Scotland’s unique fusion of academic excellence, industry collaboration, and national vision is building a globally competitive ecosystem that is ready to transform the future of healthtech, life sciences, and beyond.

A new report by Deloitte has officially named Edinburgh the UK’s leading hub for artificial intelligence, especially in healthcare applications. This recognition strengthens Scotland’s already commanding position in AI, data science, and advanced modelling. Backed by more than 60 years of cutting-edge research and supported by a world-class talent pipeline from academia to industry, Scotland is not only producing the brightest AI minds but also equipping them to tackle some of the world’s most urgent challenges. The nation’s focus on ethical AI and interdisciplinary problem-solving has become a blueprint for responsible innovation.

Unlike regions that have rushed to build AI capability in response to market trends, Scotland’s depth of expertise is rooted in decades of structured learning and research. Its universities have long been centres of AI education, producing generations of leaders who now drive global projects or mentor the next wave of talent. Programmes like The Data Lab connect students directly with industry, giving them real-world experience that spans healthcare, finance, climate science, and policymaking. Scotland’s unwavering commitment to data literacy and ethical AI ensures that this workforce is prepared not just to innovate, but to do so with purpose and accountability.

Scotland’s National AI Strategy amplifies this momentum with a long-term commitment to inclusion, upskilling, and global competitiveness. This strategy builds on the country’s proud scientific legacy, stretching back to pioneers like James Clerk Maxwell and Lord Kelvin, and continuing through to today’s global influencers like Professor Andrew Morris of Health Data Research UK and Dr. Chris Holmes of the Alan Turing Institute. These leaders exemplify how Scotland’s modelling expertise is being applied to real-world impact in public health, biostatistics, and life sciences.

With the Life Sciences sector projected to reach £25 billion by 2035, Scotland is becoming a magnet for investors seeking breakthrough medtech and data-driven health innovations. Ecosystems like CodeBase are accelerating this growth, positioning Scotland as a launchpad for the next generation of healthtech companies.

This is more than theoretical. Recent industry events, such as those hosted by The Data Lab, showcase how Scotland is translating AI research into practical solutions that improve lives. Dr. Nicolas Rattray’s pioneering work at the University of Strathclyde is a standout example. By harnessing AI to analyse vast biological datasets, his team is uncovering biomarkers that help predict frailty in patients. This allows for personalised treatment strategies, improving recovery outcomes and reducing healthcare system pressures. His research highlights how AI can transform complexity into clarity, delivering smarter, more targeted interventions in predictive medicine.

Meanwhile, Dr. Caroline Franco from the University of Aberdeen has demonstrated the power of mathematical modelling in public health. Drawing on lessons from the COVID-19 pandemic, her work shows how expert-informed models can fill gaps when real-world data is scarce or incomplete. These models are crucial tools for policymakers, helping them make data-driven decisions that are adaptable across regions and health systems. Her collaboration with organisations like the World Health Organization underlines Scotland’s role on the global stage.

Equally important is the work of Hugh Wallace at Research Data Scotland, who is leading efforts to unlock secure, ethical access to public sector data. Wallace’s vision of a centralised Researcher Access Service aims to eliminate data silos, enabling cross-sector insights that can fuel healthtech breakthroughs. His focus on trust, governance, and societal responsibility ensures that Scotland’s data infrastructure serves not only innovation but also the public good.

What makes Scotland stand out is its ability to combine academic rigour with practical impact. Its thriving Data & AI community continues to attract researchers, policymakers, and industry leaders who are committed to aligning innovation with societal benefit. As Scotland’s Life Sciences sector scales toward its ambitious targets, the intersection of AI, data, and ethical practice will remain a defining advantage.

Scotland is home to a globally recognised ecosystem that fuses AI, data science, and responsible innovation. With a clear national strategy, world-class talent, and a collaborative industry network, it is perfectly positioned to lead the next wave of life sciences and healthtech transformation.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search